<div class="container">

<table style="width: 100%;"><tr>
<td>ACTG175</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Converted AIDS Clinical Trials Group Study 175 (source: speff2trial package)</h2>

<h3>Description</h3>

<p>ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human immunodeficiency virus type I whose CD4 T cell counts were between 200 and 500 per cubic millimeter.
</p>


<h3>Usage</h3>

<pre><code class="language-R">data(ACTG175)
</code></pre>


<h3>Format</h3>

<p>A data frame with 6417 observations from 2139 patients on the following 24 variables.
</p>

<dl>
<dt>pidnum</dt>
<dd>
<p>patient ID number</p>
</dd>
<dt>age</dt>
<dd>
<p>age in years at baseline</p>
</dd>
<dt>wtkg</dt>
<dd>
<p>weight in kg at baseline</p>
</dd>
<dt>hemo</dt>
<dd>
<p>hemophilia (0=no, 1=yes)</p>
</dd>
<dt>homo</dt>
<dd>
<p>homosexual activity (0=no, 1=yes)</p>
</dd>
<dt>drugs</dt>
<dd>
<p>history of intravenous drug use (0=no, 1=yes)</p>
</dd>
<dt>karnof</dt>
<dd>
<p>Karnofsky score (on a scale of 0-100)</p>
</dd>
<dt>oprior</dt>
<dd>
<p>non-zidovudine antiretroviral therapy prior to initiation of study treatment (0=no, 1=yes)</p>
</dd>
<dt>z30</dt>
<dd>
<p>zidovudine use in the 30 days prior to treatment initiation (0=no, 1=yes)</p>
</dd>
<dt>zprior</dt>
<dd>
<p>zidovudine use prior to treatment initiation (0=no, 1=yes)</p>
</dd>
<dt>preanti</dt>
<dd>
<p>number of days of previously received antiretroviral therapy</p>
</dd>
<dt>race</dt>
<dd>
<p>race (0=white, 1=non-white)</p>
</dd>
<dt>gender</dt>
<dd>
<p>gender (0=female, 1=male)</p>
</dd>
<dt>str2</dt>
<dd>
<p>antiretroviral history (0=naive, 1=experienced)</p>
</dd>
<dt>strat</dt>
<dd>
<p>antiretroviral history stratification (1:antiretroviral naive, 2:greater than 1 but less than 52 weeks of prior antiretroviral therapy, 3: greater than 52 weeks)</p>
</dd>
<dt>symptom</dt>
<dd>
<p>symptomatic indicator (0=asymptomatic, 1=symptomatic)</p>
</dd>
<dt>treat</dt>
<dd>
<p>treatment indicator (0=zidovudine only, 1=other therapies)</p>
</dd>
<dt>offtrt</dt>
<dd>
<p>indicator of off-treatment before 96 weeks (0=no,1=yes)</p>
</dd>
<dt>r</dt>
<dd>
<p>missing CD4 T cell count at 96 weeks (0=missing, 1=observed)</p>
</dd>
<dt>cens</dt>
<dd>
<p>indicator of observing the event in days</p>
</dd>
<dt>days</dt>
<dd>
<p>number of days until the first occurrence of: (i) a decline in CD4 T cell count of at least 50 (ii) an event indicating progression to AIDS, or (iii) death.</p>
</dd>
<dt>arms</dt>
<dd>
<p>treatment arm (0=zidovudine, 1=zidovudine and didanosine, 2=zidovudine and zalcitabine, 3=didanosine)</p>
</dd>
<dt>time</dt>
<dd>
<p>time in weeks</p>
</dd>
<dt>cd4</dt>
<dd>
<p>CD4 T cell count</p>
</dd>
</dl>
<h3>References</h3>

<p>Hammer, S.M., et al. (1996), A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New England Journal of Medicine, 335:1081-1090.
</p>


</div>